811867-27-3Relevant academic research and scientific papers
Intermediates for macrocyclic compounds
-
, (2015/11/30)
The present invention is directed to novel macrocyclic compounds of formula (I) and their pharmaceutically acceptable salts, hydrates or solvates: wherein R1, R2, R3, R4, R5, R6, n1, m, p Z1, Z2, and Z3 are as describe in the specification. The invention also relates to compounds of formula (I) which are antagonists of the motilin receptor and are useful in the treatment of disorders associated with this receptor and with or with motility dysfunction.
Discovery of a new class of macrocyclic antagonists to the human motilin receptor
Marsault, Eric,Hoveyda, Hamid R.,Peterson, Mark L.,Saint-Louis, Carl,Landry, Annick,Vézina, Martin,Quellet, Luc,Wang, Zhigang,Ramaseshan, Mahesh,Beaubien, Sylvie,Benakli, Kamel,Beauchemin, Sophie,Déziel, Robert,Peeters, Théo,Fraser, Graeme L.
, p. 7190 - 7197 (2007/10/03)
A novel class of macrocyclic peptidomimetics was identified and optimized as potent antagonists to the human motilin receptor (hMOT-R). Well-defined structure-activity relationships allowed for rapid optimization of potency that eventually led to high aff
